ChromaDex
 |
|
| Public | |
| Traded as | OTCQX:CDXC |
| Industry | Pharmaceuticals, Natural products, Ingredients |
| Founded | 1999 |
| Headquarters | Irvine, California, United States |
|
Key people
|
Frank Jaksch (Co-Founder, CEO) |
| Products | pTeroPure, NIAGEN (Nicotinamide Riboside), PURENERGY, ProC3G |
| Website | ChromaDex.com |
ChromaDex is a publicly traded natural products company based in Irvine, California. The company is most well known for its industry standard phytochemical testing laboratories and catalogue. In cooperation with the University of Mississippi, the company is currently exploring the effects of pterostiibene on humans.
ChromaDex has licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound trademarked as pTeroPure via the company's BluScience product line.
In 2010, ChromaDex won the North American Frost & Sullivan Award for Most Promising Ingredient of the Year for pTeroPure pterostilbene.
In 2016, ChromaDex achieved GRAS status for its patented nicotinamide riboside product, NIAGEN, which allows it to be marketed in the food and beverage industries. ChromaDex also initiated a 2nd human clinical trial on NIAGEN, to examine the benefits if taken daily for eight consecutive weeks. In addition, ChromaDex was named as part of the OTCQX Best 50.
American billionaire and pharmaceutical entrepreneur Phillip Frost owns approximately 19% of ChromaDex.
ChromaDex was founded in 1999. According to a Standard & Poor's research report, the company was created "in response to growing demand for natural product reference standards, materials and services. It has worked to establish itself as an industry leader in nutraceutical and botanical certification, and even publishes its own manual outlining specifications for ." On July 14, 2008 ChromaDex merged with CDI Acquisition, a subsidiary of Cody Resources Inc. On July 29, 2008 the company completed a private placement agreement, which yielded gross proceeds of $4.67 million.
Later in 2008, ChromaDex (OTCQX: ) became a publicly traded company. Shares of ChromaDex are traded on the OTC Markets QX Marketplace. As of April 2015, there were 108 million shares outstanding.
...
Wikipedia